LINC00376: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC00376

NCBI ID: G104355293

LINC00376

Other Name(s): Long intergenic non-protein coding RNA 376 | long intergenic non-protein coding RNA 376

LINC00376: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC00376 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its unique 3'-end, a feature that is not observed in typical lncRNAs. LINC00376 has been predicted to play a crucial role in various cellular processes, including cell adhesion, migration, and transcriptional regulation. Its functions as a drug target or biomarker are of great interest due to its potential impact on human health.

Drug Target Potential

LINC00376 has been predicted to interact with various protein targets, including tyrosine kinases, G protein-coupled receptors, and nuclear factor kappa B (NF-kappa-B). Its expression has been shown to be regulated by various signaling pathways, including NF-kappa, NF-kappa-B, and PI3K/AKT signaling pathways. These signaling pathways are involved in various cellular processes, including cell growth, differentiation, and survival. Therefore, targeting LINC00376 may provide new insights into the mechanisms underlying cellular processes and potential therapeutic interventions.

Biomarker Potential

LINC00376 has been predicted to be involved in various biological processes, including cell adhesion, migration, and transcriptional regulation. Its functions as a biomarker have been studied in various disease models, including cancer, neurodegenerative diseases, and developmental disorders. For example, LINC00376 has has been shown to be involved in the regulation of cell adhesion in various tissues, including cancer cells. Its expression has also been associated with the progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Therefore, LINC00376 may be a valuable biomarker for the diagnosis and treatment of these diseases.

Functional Characterization

To further understand the functions of LINC00376, its expression and localization have been studied in various cellular contexts. The expression of LINC00376 has been shown to be regulated by various signaling pathways, including NF-kappa, NF-kappa-B, and PI3K/AKT signaling pathways . It has been shown to be expressed in various tissues and cellular compartments, including the cytoplasm, the endoplasmic reticulum, and the nuclear envelope.

Functional assays have also been used to study the localization of LINC00376 in various cellular contexts. The results of these assays have shown that LINC00376 is primarily localized to the endoplasmic reticulum and the cytoplasm. It is also shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Conclusion

In conclusion, LINC00376 is a long intergenic non-protein-coding RNA that has been identified in various organisms, including humans. Its unique 3'-end and predicted function as a drug target or biomarker make it an attractive target for further study. Further research is needed to understand the mechanisms underlying its functions and its potential as a therapeutic intervention.

Protein Name: Long Intergenic Non-protein Coding RNA 376

The "LINC00376 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00376 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets